Lestaurtinib is primarily investigated for its potential in treating various types of cancer, particularly acute myeloid leukemia (AML) and myeloproliferative disorders. It functions as a multi-kinase inhibitor, notably targeting FLT3 tyrosine kinase, which plays a key role in cancer cell proliferation, and blocking specific enzymes that promote cancer cell growth and survival. This mechanism makes it a candidate for combination therapies with other chemotherapeutic agents to enhance treatment efficacy. Additionally, lestaurtinib is being studied for its role in managing solid tumors and its potential to overcome drug resistance in certain cancers, especially those with FLT3 mutations. Research also explores its application in reducing inflammation and fibrosis in non-cancerous conditions, leveraging its inhibitory effects on kinase pathways involved in these processes. Clinical trials continue to evaluate its safety, dosage, and effectiveness in diverse therapeutic contexts.